NOE-101 (basimglurant)
Trigeminal Neuralgia
Key Facts
About Noema Pharma
Noema Pharma is a private, pre-revenue biotech advancing a pipeline of small-molecule therapies targeting central nervous system disorders. Its lead assets, acquired from Roche, are in Phase 2b development for conditions like trigeminal neuralgia and treatment-resistant depression, representing significant unmet needs. The company is backed by experienced life science investors and led by a team with deep CNS and biopharma expertise, positioning it to potentially bring new treatment options to challenging neurological markets.
View full company profileAbout Noema Pharma
Noema Pharma is a private, pre-revenue biotech advancing a pipeline of small-molecule therapies targeting central nervous system disorders. Its lead assets, acquired from Roche, are in Phase 2b development for conditions like trigeminal neuralgia and treatment-resistant depression, representing significant unmet needs. The company is backed by experienced life science investors and led by a team with deep CNS and biopharma expertise, positioning it to potentially bring new treatment options to challenging neurological markets.
View full company profileTherapeutic Areas
Other Trigeminal Neuralgia Drugs
| Drug | Company | Phase |
|---|---|---|
| Neurology Program | Kriya Therapeutics | Unknown |